Central monitoring refers to the risk-based, centralised oversight of clinical trials through systematic analysis of study data – without physical presence at the investigational site. In contrast to traditional on-site monitoring, in which a monitor regularly visits the investigational site, central monitoring involves statistically evaluating data from the Electronic Data Capture system and other study sources to identify anomalies, data errors and potential compliance issues at an early stage. Central monitoring is a key element of the modern risk-based monitoring approach, which is firmly embedded in the ICH E6(R3) GCP guideline and is expressly recommended by the EMA and FDA as a preferred monitoring strategy.
Regulatory basis
The ICH E6(R3) GCP guideline expressly recommends a risk-based approach to the oversight of clinical trials and recognises central monitoring as an equivalent or complementary alternative to purely on-site strategies. With its Reflection Paper on Risk-Based Quality Management (EMA/269011/2013), the EMA has created the European framework for flexible monitoring strategies. In its guidance “A Risk-Based Approach to Monitoring of Clinical Investigations” (2013), the FDA has likewise established central monitoring as a recognised procedure. A prerequisite is a documented monitoring plan describing the selection and justification of central monitoring activities as well as the Key Risk Indicators and escalation thresholds used, which is archived in the Trial Master File. During inspections, authorities expect this plan to have been consistently implemented and fully documented. An incomplete or unimplemented monitoring plan is considered a critical GCP finding and can jeopardise the usability of the entire study dataset.
Methods and tools
Central monitoring encompasses a variety of data-driven analyses:
- Statistical outlier analysis: comparison of data points from one site with the overall average across all sites – deviations indicate data errors or manipulation.
- Key Risk Indicators (KRIs): metrics such as protocol deviation rate, screen failure rate, query rate and informed consent error rate are continuously monitored.
- Key Performance Indicators (KPIs): operational metrics on study performance – recruitment rate, data entry speed, visit compliance.
- Data completeness checks: automated checks for missing mandatory fields, inconsistent date entries and logical inconsistencies in the dataset.
- Signal detection: early detection of safety signals by monitoring adverse events at site level compared with the overall study.
Specialised software platforms such as Medidata Rave Detect or study-specific dashboards support central monitoring through automated reports and real-time visualisations of study data. The signals generated feed into ongoing risk assessment and determine the intensity of subsequent on-site visits. Threshold values for KRIs are typically defined before study start in a structured risk assessment workshop involving the sponsor, CRO and biometrics, and are documented as mandatory in the monitoring plan. Regular review of these thresholds during the ongoing trial is part of good monitoring practice.
Integration into the risk-based monitoring strategy
Central monitoring is a component of an overarching risk-based monitoring strategy. Based on ongoing central monitoring results, it is dynamically decided which investigational sites require more intensive on-site visits and which can be visited less frequently. Sites with repeatedly conspicuous signals can be prioritised at short notice for an unplanned for-cause visit. This adaptive resource management considerably reduces overall monitoring costs without compromising study data quality. The combination of central monitoring, remote monitoring and risk-adapted on-site visits is now regarded as international best practice in clinical research. Sponsor and CRO should review the strategy after the first recruitment quarter and adjust it as needed to deploy resources specifically where the risk is highest.
Significance for clinical trials
Central monitoring increases data quality, enables early problem detection and considerably reduces operational effort compared with purely on-site-based strategies. Studies with large participant numbers and many international investigational sites particularly benefit, as systemic errors and site outliers are detected across sites – often considerably earlier than under purely reactive on-site strategies, where problems only come to light at the next scheduled visit. The EMA and FDA explicitly accept risk-based monitoring strategies as equivalent to traditional 100% SDV approaches, provided that methodology and responses to signals are fully documented. Studies with established central monitoring programmes show, in practice, a lower rate of critical GCP deviations and higher data quality in statistical analysis. Full-service CROs such as mediconomics implement central monitoring frameworks, including KRI/KPI definition, statistical analysis models, automated reporting dashboards and clear escalation protocols – tailored to the specific risk profiles of the respective study and indication.
Frequently Asked Questions (FAQ)
Can central monitoring completely replace on-site monitoring?
In practice, central monitoring does not completely replace on-site visits but specifically reduces their frequency and intensity. Certain activities – such as source data verification or the checking of physical documents – still require physical presence. The risk-based monitoring approach defines the ratio in which both methods are used, based on the risk profile.
What data is analysed in central monitoring?
Central monitoring primarily analyses data from the Electronic Data Capture system: patient data, vital signs, laboratory data, adverse events, protocol deviations and data entry metadata. Data from the Interactive Response Technology system and operational data from the Trial Management System can additionally be included.
How are central monitoring findings documented?
All central monitoring activities, analysed metrics, identified signals and actions taken are documented in the Trial Master File. Central monitoring reports must be presented during regulatory inspections. Complete, timely documentation of the methodology, the defined thresholds and the specific responses to identified signals is a regulatory requirement and forms the basis for a successful regulatory inspection by the EMA, BfArM or FDA.
Regulatory references
- ICH E6(R3) GCP guideline: Risk-Based Monitoring, Central Monitoring
- EMA Reflection Paper on Risk-Based Quality Management (EMA/269011/2013)
- FDA Guidance: A Risk-Based Approach to Monitoring of Clinical Investigations (2013)
- Regulation (EU) 536/2014 (CTR): monitoring requirements for clinical trials
- TransCelerate BioPharma: Risk-Based Monitoring Methodology (2013)